Copyright
©The Author(s) 2016.
World J Surg Proced. Mar 28, 2016; 6(1): 13-18
Published online Mar 28, 2016. doi: 10.5412/wjsp.v6.i1.13
Published online Mar 28, 2016. doi: 10.5412/wjsp.v6.i1.13
Gene | Cancer risk1 |
ATM | Breast, pancreatic cancer |
BARD1 | Breast |
BRCA1 | Breast, ovarian, male breast cancer, melanoma, pancreatic cancer |
BRCA2 | Breast, ovarian, male breast cancer, melanoma, pancreatic, prostate cancer |
BRIP1 | Breast |
CDH1 | Breast, diffuse-type gastric cancer |
CHEK2 | Breast, colon, ovarian |
EPCAM | Colorectal, uterine, stomach, ovarian |
MLH1 | Colorectal, uterine, stomach, ovarian |
MRE11A | Breast |
MSH2 | Colorectal, uterine, ovarian |
MSH6 | Colorectal, uterine, stomach, ovarian |
MUTYH | Breast, colorectal, other gastrointestinal sites |
NBN | Breast |
NF1 | Breast, peripheral nerve sheath tumors, gliomas, leukemias, pheochromocytomas |
PALB2 | Breast, pancreatic cancer |
PMS2 | Colorectal, uterine, stomach, ovarian |
PTEN | Breast, thyroid, endometrial cancer |
RAD50 | Breast |
RAD51C | Breast, ovarian |
RAD51D | Breast, ovarian |
STK11 | Breast, gastrointestinal, ovarian |
TP53 | Breast, ovarian, osteosarcomas, brain tumors, colorectal, other gastrointestinal sites |
- Citation: Kapoor NS, Banks KC. Should multi-gene panel testing replace limited BRCA1/2 testing? A review of genetic testing for hereditary breast and ovarian cancers. World J Surg Proced 2016; 6(1): 13-18
- URL: https://www.wjgnet.com/2219-2832/full/v6/i1/13.htm
- DOI: https://dx.doi.org/10.5412/wjsp.v6.i1.13